大唐药业(836433) - 2022 Q4 - 年度业绩预告

Financial Performance - The company's net profit attributable to shareholders for 2022 is expected to be 14.11 million yuan, a decrease of 77.23% compared to 61.95 million yuan in the previous year[3]. - The decline in revenue and net profit is primarily due to the complex and severe COVID-19 prevention and control situation in Hohhot, where the company operates[4]. - The fourth quarter of 2022 saw a significant drop in revenue, which is typically the company's peak sales season, due to the severe impact of the pandemic[5]. - The financial data in the earnings forecast is preliminary and has not been audited by an accounting firm, urging investors to be cautious about investment risks[6].